Background: Corticosteroids are central to inducing remission in inflammatory bowel disease
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Corticosteroids are highly effective induction agents 7, 8 but maintenance studies have demonstrated that this effect is not durable. 8, 9 Additionally, they have well-documented side effects, such as increased infection risk, avascular bone necrosis, mood disturbance, hypothalamic-pituitary-adrenal axis suppression, osteoporosis, Cushingoid appearance and hypertension. 10 When compared against immunomodulators and biologic therapies their prolonged use remains the single greatest risk factor for increased morbidity and mortality in inflammatory bowel disease (IBD) patients. 11 Data from 1994 to 2008 demonstrated that despite advances in new therapies the relative risk of steroid exposure for IBD patients in their first 5 years from diagnosis remained static at around 50%. 12 Recognition that repeated corticosteroid use is associated with significant morbidity has led gastrointestinal societies in both the United States (US)
and United Kingdom (UK) to make "steroid free clinical remission"
and the use of steroid sparing strategies a key goal of quality care for patients with IBD. 13, 14 In the UK the IBD Standards from 2013 stipulate that steroid use should be monitored and that patients with excessive steroid use are discussed in a multi-disciplinary (MDT)
forum. 15 UK and European Crohn's and Colitis Organisation (ECCO) guidelines all stress the need for avoidance of prolonged or recurrent corticosteroid courses and suggest that corticosteroid dependant patients or those receiving more than one course of steroids in a year should be offered an immunomodulator or anti-TNF agent [16] [17] [18] The primary study aim was to determine the extent of excess steroid exposure in outpatients with IBD in the UK. The secondary study aims were to determine the level of avoidable excess steroid use, to identify patient-related and organisational factors associated with steroid excess and to demonstrate that steroid assessment in routine clinical practice is feasible.
2 | ME TH ODS
| Development of online steroid assessment tool
The authors formed a focus group to develop the design specification of a secure online assessment tool to record and audit steroid use along with relevant disease-specific data in IBD patients (Supporting information). After adjustments made in a series of pilot studies, and software programming by a professional web company, the tool comprised of between 4 and 8 context dependent questions designed to elicit sufficient data for subsequent analysis without overburdening the clinician using it. Data were stored and transmitted securely within National Health Service operated IT infrastructure.
| Study centres and patient recruitment
We collected data from unselected consecutive IBD patients attending outpatient clinics over 3 months in July-September 2015 using the assessment tool. Inclusion criteria were adult patients with a confirmed diagnosis of IBD based on internationally accepted clinical, endoscopic, histological and or radiological criteria. Study operating procedures specified that only patients with an established diagnosis and a minimum of 3 months disease duration were included; there were no other exclusion criteria. Treating clinicians were asked to categorise disease severity at the time of the clinic visit based upon a physician global assessment (PGA) using a score of 0-3. Recruitment occurred at 11 geographically diverse centres in England and
Wales, of which eight were University Teaching hospitals. Centre characteristics are displayed in Table 1 .
| Steroid use and definitions
We recorded the number of steroid courses, length of the longest steroid course, ability to taper steroids and flares on or within 3 months of steroid withdrawal, for the 12 month period preceding the clinic visit. We defined steroid dependency or excess in accordance with ECCO and UK guidelines as the presence during the 12 month period preceding the clinic visit of 1 or more of: (1) the prescription of >1 steroid course or (2) inability to wean steroids below 10 mg/day prednisolone or 3 mg/day budesonide within 3 months of starting steroids or (3) disease flare within 3 months of stopping steroids. [16] [17] [18] To determine the extent to which clinicians had sought to avoid steroid dependency or excess, we agreed a standardised list of potential reasons for steroid dependency or excess and then allocated each possibility to one of four different categories: (1) non-IBD prescribing; (2) prescribing where no alternative existed or where appropriate measures to avoid steroid dependency or excess were put in place; (3) prescribing where relevant alternatives were sub-optimally explored; (4) prescribing where relevant alternatives were not explored. For all cases meeting the criteria for steroid dependency or excess, relevant clinic letters, biochemical parameters and endoscopy reports were collated and anonymised, before being centrally allocated for blinded peer review by a co-author from a different centre, who assigned each case to one of these pre-agreed categories using a scoring template (Supporting information). Where the peer reviewer felt unable to categorise, adjudication was performed by two further blinded reviewers.
| Analysis plan
Data on steroid use and avoidability were combined with other patient data for descriptive analysis. All statistical tests were performed using R (version 3. To test the possibility that avoidability might be related to the criteria for steroid dependency or excess met, we analysed the avoidability of all cases pooled according to the criteria met. There were no significant differences between groups (Supporting information). Since the availability of >12 months of clinical data was not a specific inclusion criterion (to allow for, e.g. the inclusion of newly diagnosed patients) we analysed the impact of this in our data set.
For the 166 cases (98.2%) of steroid dependency or excess where the duration of follow-up could be accurately determined, 149
(89.8%) had >12 months of data available, whilst 17 (10.2%) had either been diagnosed or transferred care within the previous 12 months. There was no significant difference in peer review assessment of avoidability between these groups (49.0% of cases with >12 months of data, 47.1% of cases with <12 months of data,
We also recorded the type of steroid prescribed in cases meeting criteria for steroid dependency or excess, which we were able to determine from the records available in 165 cases (98%). Of these, in 130 (78.8%) cases prednisolone was the sole oral steroid prescribed whilst in 29 (17.6%), budesonide was the sole oral steroid prescribed. In six (3.6%) cases both prednisolone and budesonide were prescribed. There were no significant differences between the proportions of cases judged avoidable between these groups (data not shown).
In two cases of steroid dependency or excess (1.2%) there was a prior history of malignancy. In one of these, the steroid prescriptions were judged to have been unavoidable, whilst in the other case, there was no evidence of the consideration of alternatives, and the case was therefore judged to have been avoidable. Table 2 ). Likewise, the incidence of steroid dependency or excess in these patients was significantly higher than in those with less active disease (35.0% vs 9.6%, P < .0001).
T A B L E 2 Disease and treatment characteristics of the cohort
In those patients with moderate/severely active disease, the incidence of inappropriate steroid excess was significantly higher than in those with mild/quiescent disease (16.3% vs 4.6%; P < .0001; Figure 2 and data not shown). When restricting analysis to just those patients with moderate/ severe disease activity, UC patients had a significantly higher rate of steroid exposure than CD patients (77.2% vs 57.0%, P = .003; F I G U R E 1 Outcomes of blinded peer review of medical records for patients meeting criteria for steroid dependency or excess (whole cohort). x-axis and numbers overlaid on histogram bars show the patients in each category as a percentage of all patients in the relevant parent population for each row (including both patients meeting criteria for steroid dependency or excess and those not meeting these criteria). There were no statistically significant differences between sub-categorisation for CD and UC. Note that "probably avoidable" and "definitely avoidable" sub-categories were combined in our definition of inappropriate steroid excess 
|
Outcomes of blinded peer review of medical records for patients meeting criteria for steroid dependency or excess (moderate/ severe disease severity patients only). x-axis and numbers overlaid on histogram bars show the patients in each category as a percentage of all patients in the relevant parent population for each row, (including both patients meeting criteria for steroid dependency or excess and those not meeting these criteria). Patients with moderate/severe UC were more likely to have been exposed to steroid dependency or excess that was judged to have been unavoidable than patients with moderate/severe CD notable but in line with multiple previous studies. [21] [22] [23] It is notable that we found use of 5-ASA to treat CD to be an independent risk factor for steroid dependency or excess, suggesting that this may be a surrogate marker for quality of care. The association of 5-ASA usage in CD with inappropriate steroid exposure did not reach statistical significance.
Steroid prescription rates have been previously assessed using primary or secondary care databases from both UK and other international healthcare settings. 24, 25 These studies have reported rates of prolonged steroid exposure at broadly similar levels to those we report here. However, these prior studies were limited by their retrospective nature as well as less robust definitions of steroid excess.
A major advantage of our approach was the ability to assess the appropriateness of all instances of excess steroid prescribing. A further strength derives from the large number of data points relating to both patient-level and service-level factors which enabled us to assess for potential correlation of a wide range of independent predictor variables with both steroid dependency or excess and inappropriate steroid excess as outcome variables.
We have detected marked difference in excess steroid exposure between CD and UC. We found that patients with UC were less likely to have moderate/severe disease activity than CD patients, but nevertheless had a trend towards increased steroid dependency or excess. Patients with moderate/severe disease activity were at significantly increased risk of all measures of steroid prescribing that we considered, and within this cohort, we found that UC patients were significantly more likely than CD patients to be exposed to steroids and meet criteria for steroid dependency or excess. Nevertheless, these significantly increased rates of steroid dependency or excess in moderate/severe UC patients were attributable to prescribing decisions that were deemed to be unavoidable by a blinded peer reviewer.
The reasons for these differences may well have to do with the unique prescribing situation in the UK at the time of this audit, when anti-TNF biological agents were not generally reimbursed for use in UC, unlike their greater availability in CD. The UK National Institute of Health and Care Excellence issued revised guidelines for the prescribing of anti-TNF agents in UC early in February 2015, 26,27 but timelines for uptake of these guidelines meant just 7% of UC patients in our audit had completed induction therapy with anti-TNF therapy. Therefore, UC patients may have remained on thiopurine monotherapy longer than desirable despite ongoing active disease, likely explaining the increased rates of steroid dependency or excess seen in our UC cohort. Furthermore, since routine access to anti-TNF therapy was unavailable for UC patients during the 12 months prior to the audit, we did not include escalation to anti-TNF therapy as forming part of maximal medical therapy for UC, and hence this likely explains the observation that the increased steroid dependency or excess in moderate/severe UC compared to CD was deemed to be unavoidable. Indeed, we found that whilst maintenance anti-TNF treatment was protective against steroid dependency or excess for CD, thiopurine exposure or being newly initiated on anti-TNF treatment was associated with increased risk of steroid dependency or be an independent predictor of outcomes in our data set (data not shown).
Interestingly, we found association between steroid dependency or excess/inappropriate steroid excess and the number of gastroenterologists in training working at a centre. Although the odds ratio detected may appear at first to be small, in our regression analysis this was calculated per trainee. Since some centres had up to 10 trainees, these effects combined to give up to 2-fold increased predicted risk above baseline. The finding raises questions over training doctors receive before they are tasked with seeing IBD patients on their own and the level of supervision and feedback in clinic.
In an effort to improve the quality of care provided to IBD patients, professional organisations, patient organisations and health care providers have published standards IBD care providers are expected to meet. 14, 15, 20 However, many of these standards concern the set-up of care and process measures of care, whilst meaningful clinical outcome measures have so far not been agreed upon as routine quality indicators. The authors believe that the routine assessment of steroid excess provides a meaningful and easy to measure quality indicator in IBD care, akin to, for example, the manner in which routine capture and scrutiny of data relating to caecal intubation and adenoma detection rates transformed the quality assurance of endoscopy practice in, for example, the UK. 28, 29 It is notable that all of the data to support the present study were captured in real time during episodes of routine clinical care by the treating clinician, without the need for time-consuming retrospective audit.
Steroid prescriptions may originate from primary care physicians, many of whom may lack experience in IBD management. In our study, we identified 17% of steroid dependency or excess where prescriptions for steroids were initiated outside of specialist care. In nearly all of these cases, steroid exposure was judged to be inappropriate. Regular monitoring or audit of steroid use may allow these often "hidden" steroid prescriptions to be detected and actions taken to engage with primary care and improve access to specialist care. It is tempting to speculate that improved access to secondary care gastroenterology services might be associated with a rate of inappropriate steroid exposure lower than the 7.1% we observed in our cohort. However, it is salutary to note that for those patients exposed to excess steroid where all prescriptions were initiated from secondary care, the proportion judged to have received inappropriate steroid exposure was still 42.0% suggesting room for optimisation beyond simply increased availability of secondary care services and advice.
There are a number of limitations to our study. First, while the centres included cover a wide geographical region, and include both university teaching hospitals and district general hospitals, the centres were self-selecting, potentially introducing a degree of selection bias, although importantly rates of biologics and thiopurine use are broadly similar to those of previous nationwide audits. We cannot assume that our findings automatically apply to other centres within the UK, or indeed to other countries or different healthcare settings.
Clearly, further studies are required to determine the levels of steroid excess and associated factors in these settings. For example, the degree of supervision provided for gastroenterologists in training may vary between different healthcare systems, as might the structure and function of IBD MDT meetings. Second, we deliberately chose to perform this study as a clinical audit using a tool designed to allow for rapid data collection in clinic. While this allowed us to collect accurate, prospective data on unselected patients and reduce selection bias, the amount of data that can be collected in this setting was limited, including, for example, the use of a PGA rather than a more detailed or better validated record of disease activity. Several additional aspects of patient data would have been of interest but were beyond the scope of a clinical audit. Third, it is important to point out that although we have established important associations between patient and service level factors and steroid excess, which should inform discussion on quality of care, we cannot draw firm conclusions on causality. Finally, although we enquired specifically about prescriptions initiated by other prescribers, including those in primary care, we did not have access to primary care prescription databases, making it possible that patient recall of steroid prescriptions from such settings led to underreporting.
In conclusion, we have demonstrated that 7% of UK IBD outpatients received courses of steroids in excess of international guidelines during the preceding year that might have been avoidable.
Measuring steroid dependency or excess in routine clinical practice is feasible and could form part of on-going quality improvement programs.
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